T1	Participants 488 549	Twenty six postmenopausal women with climacteric symptoms wer
T2	Participants 638 825	The women received 2 mg oral estradiol (E(2)) continuously during two 28-day cycles and 800 mg of vaginal progesterone or placebo sequentially for the last 14 days of each treatment cycle
